Skeletal muscle loss and sarcopenia in obesity pharmacotherapy

IF 31 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Nature Reviews Endocrinology Pub Date : 2024-09-18 DOI:10.1038/s41574-024-01041-4

David C. D. Hope, Tricia M-M Tan

引用次数: 0

Abstract

Pharmacological therapies with incretin-based ‘multi-agonists’ are rapidly advancing the therapeutic landscape for obesity. The loss of skeletal muscle mass with these potent weight-loss agents is emerging as a possible side effect. It is therefore important to determine whether multi-agonists increase the risk of sarcopenia in susceptible patients.

查看原文本刊更多论文

肥胖症药物治疗中的骨骼肌损失和肌肉疏松症

以增量素为基础的 "多拮抗剂 "药物疗法正在迅速推进肥胖症的治疗。这些强效减肥药可能产生的副作用是骨骼肌质量下降。因此，确定多种激动剂是否会增加易感患者患肌肉疏松症的风险非常重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Endocrinology 医学-内分泌学与代谢

CiteScore

42.00

自引率

0.70%

发文量

158

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Endocrinology aspires to be the foremost platform for reviews and commentaries catering to the scientific communities it serves. The journal aims to publish articles characterized by authority, accessibility, and clarity, enhanced with easily understandable figures, tables, and other visual aids. The goal is to offer an unparalleled service to authors, referees, and readers, striving to maximize the usefulness and impact of each article. Nature Reviews Endocrinology publishes Research Highlights, Comments, News & Views, Reviews, Consensus Statements, and Perspectives relevant to researchers and clinicians in the fields of endocrinology and metabolism. Its broad scope ensures that the work it publishes reaches the widest possible audience.